Key points in Resmetirom therapy for metabolic dysfunction-associated steatotic liver disease: October 2024 updates to AASLD practice guidance
10.3760/cma.j.cn311367-20250313-00106
- VernacularTitle:美国肝病学会《瑞美替罗治疗代谢功能障碍相关脂肪性肝病实践指南(2024年10月更新版)》摘译
- Author:
Na ZHANG
1
;
Guohong HAN
1
Author Information
1. 西安国际医学中心医院消化与外周血管介入科，西安 710100
- Publication Type:Journal Article
- Keywords:
Metabolic dysfunction-associated steatotic liver disease;
Resmetirom;
Treatment
- From:
Chinese Journal of Digestion
2025;45(5):289-292
- CountryChina
- Language:Chinese
-
Abstract:
Resmetirom received accelerated approval from the United States Food and Drug Administration (FDA) in March 2024 for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) with moderate to advanced liver fibrosis (stages F2 to F3 fibrosis). This article is excerpted from the Resmetirom therapy for metabolic dysfunction- associated steatotic liver disease: October 2024 updates to AASLD practice guidance. The purpose of this article is to provide medication guidance to clinicians.
